Posted by Michael Wonder on 08 Mar 2019
Direct-acting anti-virals for hepatitis C - outcome statement
8 March 2019 - The outcome statement for the direct-acting anti-virals for hepatitis C stakeholder meeting held on 13 December 2018 is now available.
The objective of the stakeholder meeting was to receive advice and clinical perspectives on potential changes to the prescribing requirements for PBS subsidised access to direct-acting antiviral (DAA) regimens for treatment of chronic hepatitis C (CHC) infection. The PBAC Chair noted that the meeting provided the opportunity to build upon earlier written consultation with key stakeholders undertaken in May/June 2018.
Stakeholders noted that utilisation and uptake of the DAA therapies in 2016 was higher than anticipated. This was despite the extensive consultation undertaken before the listing of DAAs to estimate the number of patients awaiting these therapies.
